Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Gepubliceerd in:
Introduction hoofdstuk lezen eerste hoofdstuk lezen

2014 | OriginalPaper | Hoofdstuk

3. Recurrent and Founder Mutations in the Netherlands: the Long-QT Syndrome*

Auteurs : N. Hofman, R. Jongbloed, P. G. Postema, E. Nannenberg, M. Alders, A. A. M. Wilde

Gepubliceerd in: Founder mutations in inherited cardiac diseases in the Netherlands

Uitgeverij: Bohn Stafleu van Loghum

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Samenvatting

Background and objective

The long-QT syndrome (LQTS) is associated with premature sudden cardiac deaths affecting whole families and is caused by mutations in genes encoding for cardiac proteins. When the same mutation is found in different families (recurrent mutations), this may imply either a common ancestor (founder) or multiple de novo mutations. We aimed to review recurrent mutations in patients with LQTS.

Methods

By use of our databases, we investigated the number of mutations that were found recurrently (at least three times) in LQT type 1–3 patients in the Netherlands. We studied familial links in the apparently unrelated probands, and we visualised the geographical distribution of these probands. Our results were compared with published literature of founder effects in LQTS outside the Netherlands.

Results

We counted 14 recurrent LQT mutations in the Netherlands. There are 326 identified carriers of one of these mutations. For three of these mutations, familial links were found between apparently unrelated probands.

Conclusion

Whereas true LQT founder mutations are described elsewhere in the world, we cannot yet demonstrate a real founder effect of these recurrent mutations in the Netherlands. Further studies on the prevalence of these mutations are indicated, and haplotype-sharing of the mutation carriers is pertinent to provide more evidence for founder mutation-based LQTS pathology in our country.
vorige hoofdstuk Founder mutations among the Dutch*
volgende hoofdstuk Founder mutations in the Netherlands: SCN5a 1795insD, the first described arrhythmia overlap syndrome and one of the largest and best characterised families worldwide*
Literatuur
1.
Schwartz PJ, Stramba-Badiale M, Crotti L, Pedrazzini M, Besana A, Bosi G, et al. Prevalence of the congenital long-QT syndrome. Circulation. 2009;120:1761–7.CrossRefPubMedPubMedCentral
2.
Moss AJ, Robinson JL, Gessman L, Gillespie R, Zareba W, Schwartz PJ, et al. Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. Am J Cardiol. 1999;15:876–9.CrossRef
3.
Wilde AAM, Jongbloed RJE, Doevendans PA, Düren DR, Hauer RN, van Langen IM, et al. Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS) patients from KVLQT1-related patients (LQTS). J Am Coll Cardiol. 1999;33:327–32.CrossRefPubMed
4.
Ackerman MJ, Tester DJ, Porter CJ. Swimming, a gene-specific arrhythmogenic trigger for inherited long QT syndrome. Mayo Clin Proc. 1999;74:1088–94.CrossRefPubMed
5.
Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, et al. Genotype–phenotype correlation in the long QT syndrome. Specific triggers for life-threatening arrhythmias. Circulation. 2001;103:89–95.CrossRefPubMed
6.
Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Robinson J, Priori SG, et al. Influence of genotype on the clinical course of the long-QT syndrome. N Engl J Med. 1998;339:960–5.CrossRefPubMed
7.
Hofman N, Wilde AA, Kääb S, van Langen IM, Tanck MW, Mannens MM, et al. Diagnostic criteria for congenital long QT syndrome in the era of molecular genetics: do we need a scoring system? Eur Heart J. 2007;28:575–80.CrossRefPubMed
8.
Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, et al. Risk stratification in the long-QT syndrome. New Engl J Med. 2003;348:1866–74.CrossRefPubMed
9.
Tan HL, Bardai A, Shimizu W, Moss AH, Schulze-Bahr E, Noda T, et al. Genotype-specific onset of arrhythmias in congenital long-QT syndrome: possible therapy implications. Circulation. 2006;114:2096–103.CrossRefPubMed
10.
Marjamaa A, Salomaa V, Newton-Cheh C, Porthan K, Reunanen A, Karanko H, et al. High prevalence of four long QT syndrome founder mutations in the Finnish population. Ann Med. 2009;41:234–40.CrossRefPubMedPubMedCentral
11.
Brink PA, Crotti L, Corfield V, Goosen A, Durrheim G, Hedley P, et al. Phenotypic variability and unusual clinical severity of congenital long-QT syndrome in a founder population. Circulation. 2005;112:2602–10.CrossRefPubMed
12.
13.
Crotti L, Spazzolini C, Schwartz PJ, Shimizu W, Denjoy I, Schulze-Bahr E, et al. The common long-QT syndrome mutation KCNQ1/A341V causes unusually severe clinical manifestations in patients with different ethnic backgrounds: toward a mutation-specific risk stratification. Circulation. 2007;116:2366–75.CrossRefPubMed
14.
Winbo A, Diamant UB, Stattin EL, Jensen SM, Rydberg A. Low incidence of sudden cardiac death in a Swedish Y111C type 1 long-QT syndrome population. Circ Cardiovasc Genet. 2009;2:558–64.CrossRefPubMed
15.
Fodstad H, Swan H, Laitinen P, Piipo K, Paavonen K, Viitasalo M, et al. Four potassium channel mutations account for 73% of the genetic spectrum underlying long-QT syndrome (LQTS) and provide evidence for a strong founder effect in Finland. Ann Med. 2004;36:53–63.CrossRefPubMed
16.
Bhuiyan ZA, Al-Shahrani S, Al-Khadra AS, Al-Ghamdi S, Al-Khalaf K, Mannens MMAM, et al. Clinical and genetic analysis of long QT syndrome in children from six families in Saudi Arabia: are they different? Pediatr Cardiol. 2009;30:490–501.CrossRefPubMed
17.
18.
Kapa S, Tester DJ, Salisbury BA, Harris-Kerr C, Pungliya MS, Alders M, et al. Genetic testing for long-QT syndrome: distinguishing pathogenic mutations from benign variants. Circulation. 2009;120:1752–60.CrossRefPubMedPubMedCentral
19.
Kapplinger JD, Tester DJ, Salisbury BA, Carr JL, Harris-Kerr C, Pollevick GD, et al. Spectrum and prevalence of mutations from the first 2500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test. Heart Rhythm. 2009;6:1297–303.CrossRefPubMedPubMedCentral
20.
Bezzina C, Veldkamp MW, van den Berg MP, Postma AV, Rook MB, Viersma JW, et al. A single Na (+) channel mutation causing both long-QT and Brugada syndromes. Circ Res. 1999;85:1206–13.CrossRefPubMed
21.
Postema PG, van den Berg MP, van Tintelen JP, van den Heuvel F, Grundeken N, Hofman N, et al. SCN5A 1795insD, the first described arrhythmia overlap syndrome and one of the largest and best characterized families worldwide. Neth Heart J. 2009;17:422–8.CrossRefPubMedPubMedCentral
22.
Moss AJ, Shimizu W, Wilde AA, Towbin JA, Zareba W, Robinson JL, et al. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation. 2007;115:2481–9.CrossRefPubMedPubMedCentral
23.
Antonarakis SE, Krawczak M, Cooper DN. Disease-causing mutations in the human genome. Eur J Pediatr. 2000;159:S173–8. Supplement 3.CrossRefPubMed
24.
Shimizu W, Moss AJ, Wilde AAM, Towbin JA, Ackerman MJ, January CT. Genotype–phenotype aspects of type 2 long QT syndrome. J Am Coll Cardiol. 2009;54:2052–62.CrossRefPubMedPubMedCentral
25.
Anderson CL, Delisle BP, Anson BD, Kilby JA, Will ML, Tester DJ, et al. Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient mechanism. Circulation. 2006;113:365–73.CrossRefPubMed
26.
Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, et al. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation. 2000;102:1178–85.CrossRefPubMed
27.
Tester DJ, Will ML, Haglund CM, Ackerman MJ. Effect of clinical phenotype on yield of long QT syndrome genetic testing. J Am Coll Cardiol. 2006;47:764–8.CrossRefPubMed
28.
Napolitano C, Priori SG, Schwartz PJ, Bloise R, Ronchetti E, Nastoli J, et al. Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA. 2005;294:2975–80.CrossRefPubMed
29.
Hofman N, Tan HL, van Langen IM, Birnie E, Mannens MMAM, et al. Primary inherited electrical heart disease: a ten year experience in the Netherlands. Circulation. 2006;114:II–723. abstract.
30.
Crotti L, Cristina M, Insolia R, Peljto A, Goosen A, Brink PA, et al. NOS1AP is a genetic modifier of the long-QT syndrome. Circulation. 2009;120:1657–63.CrossRefPubMedPubMedCentral
Metagegevens
Titel
Recurrent and Founder Mutations in the Netherlands: the Long-QT Syndrome*
Auteurs
N. Hofman
R. Jongbloed
P. G. Postema
E. Nannenberg
M. Alders
A. A. M. Wilde
Copyright
2014
Uitgeverij
Bohn Stafleu van Loghum
Boek
Founder mutations in inherited cardiac diseases in the Netherlands

Print ISBN: 978-90-368-0704-3

Elektronisch ISBN: 978-90-368-0705-0

Copyright: 2014

DOI
https://doi.org/10.1007/978-90-368-0705-0_3